TY - JOUR T1 - Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical <em>In Vivo</em> Models JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 451 LP - 464 DO - 10.21873/cgp.20149 VL - 16 IS - 6 AU - ULRICH H. WEIDLE AU - FABIAN BIRZELE AU - ADAM NOPORA Y1 - 2019/11/01 UR - http://cgp.iiarjournals.org/content/16/6/451.abstract N2 - Patients with pancreatic ductal adenocarcinoma have a dismall prognosis because at the time of diagnosis, in the vast majority of patients the tumor has already disseminated to distant organs and the therapeutic benefit of approved agents such as gemcitabine is limited. Therefore, the identification and preclinical and clinical validation of therapeutic agents covering new targets is of paramount importance. In this review we have summarized microRNAs and corresponding targets which affect growth and metastasis of pancreatic tumors in preclinical mouse in vivo models. We identified four up-regulated and 16 down-regulated miRs in PDAC in comparison to corresponding normal tissues. Three sub-categories of miRs have emerged: miRs affecting tumor growth and miRs with an impact on both, tumor growth and metastasis or metastasis only. Finally, we discuss technical and therapeutic aspects of miR-related therapeutic agents for the treatment of pancreatic ductal adenocarcinoma. ER -